- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04077580
The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI (ImpresUWP3)
The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing Due to New Episodes of Urinary Tract Infections (UTI) in Elderly Women With Recurrent UTI - a Triple- Blinded, Randomized Placebo-controlled Phase IV Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale for conducting this study:
Existing knowledge suggests that methenamine hippurate is a safe drug with few and mild side effects and with the potential to significantly reduce antibiotic usage for women with recurrent UTIs. Methenamine hippurate has been on the market for a long time but has never been tested to prevent recurrent UTIs in larger RCTs with long time follow-up. Hence, this must be proven in a large randomised trial before recommending large scale use of this drug.
The primary objective of this study is to investigate if taking methenamine hippurate reduce the need for antibiotic usage due to recurrent UTI (measured as number of antibiotic courses). Pyelonephritis, hospitalization and death will be registered as safety endpoints in the study.
Study design: Triple- blinded randomised controlled phase IV trial where patients are randomised to active intervention (methenamine hippurate) or controls (placebo). We will include women aged ≥ 70 years with recurrent UTIs, defined as ≥ 3 episodes of antibiotic treated acute cystitis (acute symptoms specific/related to the urinary tract) during the last twelve months or ≥ 2 episodes during the last six months.
Setting and study population:
Women aged ≥ 70 years with recurrent UTIs in primary care. A total of 400 patients will be randomized in this trial, with approximately 100 patients in each of the participating countries; Norway, Sweden, Poland and the Netherlands. The patients will be treated for 6 months.
Patients will be enrolled August-December 2019, including screening for eligibility and getting informed consent.
Start of study with drugs is from October 1st 2019.
Primary outcome: Number of UTI antibiotic treatments during the six months of treatment. If the participant receives >1 antibiotic courses for UTI without symptom relief it is regarded as one episode and counted as one antibiotic treatment. If there has been an asymptomatic period of at least 14 days in-between two UTI antibiotic courses, this is regarded as a new antibiotic treatment. Outcomes will be assessed after 6 and 12 months
In the analysis standard linear regression will be used where number of UTI antibiotic treatments will be the dependent variable. Group allocation together with the confounding variables above will be independent variables. The dependent variable will be transformed using a rank transformation in case it is not normally distributed. A p-value will be delivered but no useful effect size if a rank transformation is used.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Utrecht, Netherlands, 3584CX,
- Universitair Medisch Centrum Utrecht
-
-
-
-
-
Oslo, Norway, NO 0317
- University of Oslo
-
-
-
-
-
Łódź, Poland, 90-153
- Medical University of Lodz,
-
-
-
-
-
Borås, Sweden, SE-503 38
- Research and Development Primary Health Care, Region Västra Götaland,
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- woman
- age ≥ 70 years
- recurrent UTIs defined as ≥ 3 episodes of antibiotic treated acute cystitis (acute symptoms specific/related to the urinary tract) during the last twelve months or ≥ 2 episodes during the last 6 months
- able and willing to comply with all trial requirements
- able and willing to give informed consent
Exclusion Criteria:
- the patient has taken methenamine hippurate within the last 12 months
- the patient is allergic to methenamine hippurate
- the patient is having current antibiotic prophylaxis for UTI
- the patient has a urinary catheter (chronic indwelling catheters as well as intermittent urinary catheterisation)
- the patient has known severe chronic renal failure or estimated creatinine glomerular filtration rate ≤ 30 ml/min (known = registered in general practice clinical records)
- the patient has a known condition or treatment associated with significant impaired immunity (e.g. long-term oral steroids, chemotherapy, or immune disorder) (known = registered in general practice (GP) clinical records)
- the patient has a known severe hepatic impairment (known = registered in GP clinical records)
- the patient is suffering from severe dehydration
- the patient has shown signs of gout
- the patient has a need for long term use of antacids such as magnesium hydroxide, magnesium carbonate, aluminium hydroxide
- the patient has a life expectancy estimated by a clinician to be less than six months
- the patient has been involved in, including completion of, follow-up procedures, in another clinical trial of an investigational medicinal product in the last 90 days
- the patient suffers from incontinence too severe to be able to provide a voided urine specimen
- the patient is participating in ImpresU Work Package 2
- the patient is suffering from significant known abnormal renal tract anatomy/physiology or neuropathic bladder disorders.
- The patient has intolerance versus lactose
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Methenamine hippurate
Tablets containing 1 g methenamine hippurate, dosage 1 tablet morning and evening.
|
Methenamine and placebo is taken 1 tablet morning and evening for 180 days
Other Names:
|
Placebo Comparator: Placebo
Placebo tablets containing 1 g of lactose, with identical size, shape and stamps
|
Methenamine and placebo is taken 1 tablet morning and evening for 180 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The primary objective of this study is to investigate if taking methenamine hippurate reduces the need for antibiotic usage due to recurrent UTI (measured as number of antibiotic courses).
Time Frame: 6 months
|
Number of UTI antibiotic treatments during the six months of treatment.
If the participant receives >1 antibiotic courses for UTI without symptom relief it is regarded as one episode and counted as one antibiotic treatment.
If there has been an asymptomatic period of at least 14 days in-between two UTI antibiotic courses, this is regarded as a new antibiotic treatment.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Use of methenamine will give prolonged effect on antibiotic usage .
Time Frame: 6 months after stop of trial treatment
|
Number of UTI antibiotic treatments during the six months following completion of treatment.
|
6 months after stop of trial treatment
|
Use of methenamine will reduced incidence of UTI.
Time Frame: 6 months
|
Number of UTIs (acute symptoms specific/related to the urinary tract) during the six months of treatment.
|
6 months
|
Use of methenamine reduce severity of UTI symptoms.
Time Frame: 6 months
|
Registration of symptom severity when initiating treatment for UTI
|
6 months
|
Use of methenamine hippurate reduce duration of UTI episodes.
Time Frame: 6 months
|
Registration of number of days of symptoms during UTI episodes.
|
6 months
|
Use of methenamine will reduce complications such as pyelonephritis and hospital admission for UTI
Time Frame: 6 months
|
register complications such as pyelonephritis and hospital admission for UTI
|
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Cees Hertogh, prof.MD, Amsterdam Umc, Location Vumc
- Principal Investigator: Theo Verheij, prof. MD, UMC Utrecht
- Principal Investigator: Maciek Godycki.Cwirko, prof MD, Medical University of Lodz
- Principal Investigator: Per-Daniel Sundvall, MD PhD, Vastra Gotaland Region
Publications and helpful links
General Publications
- Lee BS, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD003265. doi: 10.1002/14651858.CD003265.pub3.
- Davis C, Rantell A. Lower urinary tract infections in women. Br J Nurs. 2017 May 11;26(9):S12-S19. doi: 10.12968/bjon.2017.26.9.S12.
- Barclay J, Veeratterapillay R, Harding C. Non-antibiotic options for recurrent urinary tract infections in women. BMJ. 2017 Nov 23;359:j5193. doi: 10.1136/bmj.j5193. No abstract available.
- Aydin A, Ahmed K, Zaman I, Khan MS, Dasgupta P. Recurrent urinary tract infections in women. Int Urogynecol J. 2015 Jun;26(6):795-804. doi: 10.1007/s00192-014-2569-5. Epub 2014 Nov 20.
- van Buul LW, van der Steen JT, Veenhuizen RB, Achterberg WP, Schellevis FG, Essink RT, van Benthem BH, Natsch S, Hertogh CM. Antibiotic use and resistance in long term care facilities. J Am Med Dir Assoc. 2012 Jul;13(6):568.e1-13. doi: 10.1016/j.jamda.2012.04.004. Epub 2012 May 9.
- Sundvall PD, Stuart B, Davis M, Roderick P, Moore M. Antibiotic use in the care home setting: a retrospective cohort study analysing routine data. BMC Geriatr. 2015 Jun 25;15:71. doi: 10.1186/s12877-015-0073-5.
- Cronberg S, Welin CO, Henriksson L, Hellsten S, Persson KM, Stenberg P. Prevention of recurrent acute cystitis by methenamine hippurate: double blind controlled crossover long term study. Br Med J (Clin Res Ed). 1987 Jun 13;294(6586):1507-8. doi: 10.1136/bmj.294.6586.1507.
- Brumfitt W, Hamilton-Miller JM, Gargan RA, Cooper J, Smith GW. Long-term prophylaxis of urinary infections in women: comparative trial of trimethoprim, methenamine hippurate and topical povidone-iodine. J Urol. 1983 Dec;130(6):1110-4. doi: 10.1016/s0022-5347(17)51709-7.
- Alberg T, Holen O, Blix HS, Lindbaek M, Bentele H, Eriksen HM. Antibiotic use and infections in nursing homes. Tidsskr Nor Laegeforen. 2017 Mar 7;137(5):357-361. doi: 10.4045/tidsskr.16.0621. eCollection 2017 Mar. English, Norwegian.
- Heltveit-Olsen SR, Sundvall PD, Gunnarsson R, Snaebjornsson Arnljots E, Kowalczyk A, Godycki-Cwirko M, Platteel TN, Koning HAM, Groen WG, Ahren C, Grude N, Verheij TJM, Hertogh CMPM, Lindbaek M, Hoye S. Methenamine hippurate to prevent recurrent urinary tract infections in older women: protocol for a randomised, placebo-controlled trial (ImpresU). BMJ Open. 2022 Nov 1;12(11):e065217. doi: 10.1136/bmjopen-2022-065217.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Urologic Diseases
- Disease Attributes
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Infections
- Recurrence
- Urinary Tract Infections
- Anti-Infective Agents
- Anti-Bacterial Agents
- Anti-Infective Agents, Urinary
- Methenamine
- Methenamine hippurate
- Methenamine mandelate
Other Study ID Numbers
- Eudract 2018-002235-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Urinary Tract Infection
-
Lawson Health Research InstituteUniversity of Western Ontario, CanadaCompletedUrinary Tract Infection | Recurrent Urinary Tract InfectionCanada
-
University of California, IrvineCompletedRecurrent Urinary Tract InfectionUnited States
-
Radboud University Medical CenterIBSA Institut Biochimique SA; Goodlife Pharma B.V.RecruitingRecurrent Urinary Tract InfectionNetherlands
-
University of SulaimaniCompletedRecurrent Urinary Tract InfectionIraq
-
IRCCS Policlinico S. MatteoCompleted
-
Beijing Institute of Disease Control and PreventionUnknownRecurrent Urinary Tract InfectionChina
-
University of California, San DiegoNYU Langone Health; American Urogynecologic SocietyCompletedRecurrent Urinary Tract InfectionUnited States
-
Hvidovre University HospitalRecruitingRecurrent Urinary Tract InfectionDenmark
-
Atlantic Health SystemNot yet recruitingRecurrent Urinary Tract Infection
-
Medical University of GrazCompletedRecurrent Urinary Tract InfectionAustria
Clinical Trials on Methenamine Hippurate 1000 MG
-
Washington University School of MedicineWithdrawnUTI | Female Urogenital Diseases | UTI - Lower Urinary Tract Infection
-
TriHealth Inc.CompletedPelvic Organ Prolapse | Urinary Tract Infections | Urinary Retention PostoperativeUnited States
-
University of PennsylvaniaCompletedUrinary Tract Infections | Catheter-Related InfectionsUnited States
-
Fundação Educacional Serra dos ÓrgãosCompletedUrinary Tract InfectionsBrazil
-
EMSCompleted
-
University Hospital, AkershusUniversity of Oslo; Karolinska Institutet; St. Olavs Hospital; FolkehelsaUnknownUrinary Tract InfectionsNorway
-
NorthShore University HealthSystemCompletedUrinary Tract Infections, RecurrentUnited States
-
Global Alliance for TB Drug DevelopmentCompletedFood Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-003)TuberculosisUnited States
-
Spero TherapeuticsRecruitingNontuberculous Mycobacterial Pulmonary Disease (NTM-PD)United States
-
Natureceuticals Sdn BhdCompleted